SEC Form 6-K Summary
Registrant: I-MAB, a foreign private issuer; the provided filing metadata identifies the company as Novabridge Biosciences, but the filing itself names I-MAB.
Reporting period: Month of December 2021; filed December 6, 2021. Commission File Number 001-39173. The registrant reports on Form 20-F.
Business Context and Financial Information
The provided text is the Form 6-K cover page and does not include operating or financial results. It identifies I-MAB’s principal executive offices in Shanghai, People’s Republic of China.
- Revenue, profit, cash flow, margins, debt, liquidity, and other financial metrics: not provided.
- The filing references Exhibit 99.1, described as a press release, but the press release content is not included in the provided text.
Material Changes, Outlook, and Risks
The filing text does not provide clear information regarding changes versus a prior period, guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Items
- Verify the registrant’s identity, because the metadata names Novabridge Biosciences while the filing names I-MAB.
- Review Exhibit 99.1 for the substantive disclosure referenced by the Form 6-K.
- Confirm whether the filing contains any financial, clinical, operational, financing, or strategic updates not included in the provided text.